Hikma Pharmaceuticals PLC (HIK)

London
Currency in GBP
1,981.00
+2.00(+0.10%)
Closed·
HIK Scorecard
Full Analysis
Has raised its dividend for 8 consecutive years
HIK is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1,972.002,004.00
52 wk Range
17.572,360.00
Key Statistics
Edit
Bid/Ask
1,969.00 / 2,200.00
Prev. Close
1,979
Open
1,973
Day's Range
1,972-2,004
52 wk Range
17.57-2,360
Volume
170.76K
Average Volume (3m)
496.96K
1-Year Change
8.97%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HIK Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2,534.47
Upside
+27.94%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth

Hikma Pharmaceuticals PLC News & Analysis

Show more

Hikma Pharmaceuticals PLC Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and specialty products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.

Employees
9500

Compare HIK to Peers and Sector

Metrics to compare
HIK
Peers
Sector
Relationship
P/E Ratio
16.6x13.0x−0.5x
PEG Ratio
0.190.080.00
Price/Book
2.6x2.0x2.6x
Price / LTM Sales
1.9x1.9x3.1x
Upside (Analyst Target)
29.9%−1.1%47.6%
Fair Value Upside
Unlock19.3%6.7%Unlock

Analyst Ratings

9 Buy
2 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 2,534.47
(+27.94% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.62%
Dividend Yield
3.13%
Industry Median 2.53%
Annualised payout
61.91
Paid unevenly
5-Years Growth
+12.70%
Growth Streak

Earnings

Latest Release
Mar 19, 2025
EPS / Forecast
0.60 / --
Revenue / Forecast
1.56B / --
EPS Revisions
Last 90 days

HIK Income Statement

FAQ

What Is the Hikma Pharma (HIK) Stock Price Today?

The Hikma Pharma stock price today is 1,981.00

What Stock Exchange Does Hikma Pharma Trade On?

Hikma Pharma is listed and trades on the London Stock Exchange stock exchange.

What Is the Stock Symbol for Hikma Pharma?

The stock symbol for Hikma Pharma is "HIK."

Does Hikma Pharma Pay Dividends? What’s The Current Dividend Yield?

The Hikma Pharma dividend yield is 3.13%.

What Is the Hikma Pharma Market Cap?

As of today, Hikma Pharma market cap is 4.37B.

What Is Hikma Pharma's Earnings Per Share (TTM)?

The Hikma Pharma EPS (TTM) is 1.62.

From a Technical Analysis Perspective, Is HIK a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Hikma Pharma Stock Split?

Hikma Pharma has split 0 times.

How Many Employees Does Hikma Pharma Have?

Hikma Pharma has 9500 employees.

What is the current trading status of Hikma Pharma (HIK)?

As of 07 Jul 2025, Hikma Pharma (HIK) is trading at a price of 1,981.00, with a previous close of 1,979.00. The stock has fluctuated within a day range of 1,972.00 to 2,004.00, while its 52-week range spans from 17.57 to 2,360.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.